Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 16/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TAF1 | P21675 | 1/20 | 0.41 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729680 | 0.91 | LIPG (0.43) | LIPGALDH1A1TNKSTAF1CECR2 | |
| SCHEMBL22729447 | 0.88 | LIPG (0.45) | LIPGALDH1A1 | |
| SCHEMBL22729449 | 0.88 | LIPG (0.45) | LIPGALDH1A1 | |
| SCHEMBL22729690 | 0.88 | LIPG (0.45) | LIPGALDH1A1 | |
| SCHEMBL22729709 | 0.85 | EPHX2 (0.39) | LIPGALDH1A1TAF1CECR2BRD9 | |
| SCHEMBL22729712 | 0.85 | EPHX2 (0.39) | LIPGALDH1A1TAF1CECR2BRD9 | |
| SCHEMBL22729552 | 0.84 | TAF1 (0.44) | ALDH1A1TAF1CECR2BRD9 | |
| SCHEMBL22729800 | 0.83 | ALDH1A1 (0.55) | ALDH1A1 | |
| SCHEMBL23116402 | 0.83 | EPHX2 (0.44) | ALDH1A1TAF1CECR2BRD9 | |
| SCHEMBL22729665 | 0.82 | KAT2B (0.47) | LIPGALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | LIPG 147/4885ALDH1A1 2626/4885L3MBTL1 1536/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | LIPG 148/4885ALDH1A1 2660/4885L3MBTL1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.